Alpha Tau Medical's Alpha DaRT technology delivers localized alpha particle radiation for solid tumors, overcoming prior range limitations. A recent Tolmar partnership brought $35 million in upfront capital, extending the cash runway through 2027. The stock is up 32% since a March buy report.
Tap to vote and see what everyone thinks.